In anticipation of the ESMO 2024 Congress, Katy Beckermann, MD, PhD, of Vanderbilt-Ingram Cancer Center, previews various clinical trials and studies to be presented, including those on immunotherapy for metastatic kidney cancer, HIF inhibition, treatments for non-clear cell kidney cancer, and novel biomarkers for predicting treatment responses. — ...
Renal Cell Carcinoma Diagnostics
Advertisement
ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth
The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment. 
Drs. Beckermann, Rathmell, and Bacigalupa highlight the potential of ACSS2 as a therapeutic target in kidney cancer.
Researchers evaluated the tissue samples of 126 treatment-naïve patients collected from a multicenter database.
Dr. Simpa Salami's research into a 15-gene prognostic signature for predicting ccRCC risk is discussed in this interview.
ACSS2 inhibition led to lowered chromatin accessibility, HIF-2α expression, and stability.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
The signature has been initially validated to improve ccRCC risk stratification and provide better treatment allocation.
The use of 89Zr PET/CT and subsequent surgery in patients treated with it demonstrated low radiation exposure levels.
Drs. Xu and Joyce explain the rationale behind recent research on plasma KIM-1, its significance as a biomarker, and more.
Kidney injury molecule-1 is a transmembrane protein that can serve as a urinary indicator of acute renal tubular injury.
Advertisement
Video Insights
Conferene Coverage
Disitamab vedotin plus pembrolizumab shows promising efficacy, manageable safety in HER2+ aUC, with a 61.1% response rate.
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
The addition of nivo to trimodality therapy may improve RFS in patients with non-metastatic muscle-invasive bladder cancer.
PFS was improved with nivolumab plus cabozantinib.
In patients with pretreated UC, BL-B01D1 demonstrated manageable safety with encouraging antitumor activity.
Enfortumab vedotin plus pembrolizumab showed consistent PFS and OS benefit across all subgroups.
